China Resources Boya Bio-pharmaceutical Group Co., Ltd.
Industry Group: Pharmaceuticals
Country/Region: China
Identifier: SHE:300294
China Resources Boya Bio-pharmaceutical Group Co Ltd is a China-based medical industry group that integrates biochemical drugs, chemical drugs, and active pharmaceutical ingredients. It is engaged in the provision of medical and health products and services. The product categories of the company include blood products, biochemical drugs, chemical medicines and others. Some of the company's blood products include human albumin, rabies immunoglobulin, intravenous human immunoglobulin and human fibrinogen.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 668 out of 845
Universe
Global Universe 12603 out of 14916
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Lotus Pharmaceutical Co., Ltd. |
32
High
|
499 out of 845 |
Tarsus Pharmaceuticals, Inc. |
32
High
|
500 out of 845 |
Zhejiang Medicine Co., Ltd. |
32.5
High
|
522 out of 845 |
Jiangzhong Pharmaceutical Co., Ltd. |
33.3
High
|
573 out of 845 |
China Resources Boya Bio-pharmaceutical Group Co., Ltd. |
35.5
High
|
668 out of 845 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
China Resources Boya Bio-pharmaceutical Group Co., Ltd.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
China Resources Boya Bio-pharmaceutical Group Co., Ltd.'s Management of ESG Material Risk is Weak